BioSpace News Archive

Drug Development

Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis.

February 29, 2024

·

19 min read

Drug Development

Biomind Labs Announces Unprecedented Positive Results of Phase 2 Clinical Trial of BMND08 for Depression & Anxiety in Alzheimer’s Disease

Biomind Labs Announces Unprecedented Positive Results of Phase 2 Clinical Trial of BMND08 for Depression Anxiety in Alzheimer’s Disease.

February 29, 2024

·

10 min read

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Evaxion Biotech A/S announces that it will host a Research & Development Day focusing on its core AI-Immunology™ platform on March 19, 2024, at 14:00 - 18:00 CET / 8:00 a.m. - 12:00 a.m. EST.

February 29, 2024

·

3 min read

Business

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2023.

February 29, 2024

·

14 min read

JCR Pharmaceuticals Celebrates Rare Disease Day 2024 and Highlights Its Commitment to the Rare Disease Community

Thursday, February 29 is Rare Disease Day (“RDD”). RDD activities aim to raise awareness of rare diseases and to improve the quality of life of individuals with rare and intractable diseases through better diagnoses and treatments.

February 29, 2024

·

4 min read

Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute

Recce Pharmaceuticals Ltd announced the continuation of work within its Anti-Infective Research Unit at the Murdoch Children’s Research Institute, to streamline its ongoing preclinical programs while investigating new indications for future clinical trials.

February 29, 2024

·

4 min read

Business

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, reported financial results for the full year 2023 and provided a fourth quarter business update.

February 29, 2024

·

16 min read

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®

Valneva SE, a specialty vaccine company, announces that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to recommend use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus.

February 29, 2024

·

7 min read

Business

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2023, and provides a corporate update.

February 29, 2024

·

16 min read

Hanvon Technology Launches Groundbreaking Fourth-Generation BP Meter Based on Korotkoff Sound Method

Hanvon Technology Co., Ltd., based in China, has launched the world’s first smart electronic BP Meter utilizing the Korotkoff sound method.

February 29, 2024

·

2 min read